Tim van Den Heuvel
Research Subjects
Tim van Den Heuvel has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
- Ohad Cohen
Division of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel-Hashomer, Israel
13 shared publications Arcelia Arrieta
Medtronic International Trading Sàrl Tolochenaz Switzerland
7 shared publicationsJavier Castañeda
Medtronic International Trading Sàrl Tolochenaz Switzerland
7 shared publicationsOhad Cohen
MiniMed International Trading Sarl Diabetes OU Tolochenaz Switzerland
7 shared publications- Javier Castañeda
Medtronic Bakken Research Center Maastricht The Netherlands
6 shared publications Goran Petrovski
Diabetes Operating Unit, Medtronic/MiniMed, Tolochenaz, Switzerland
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
The Smart MDI System in People With Type 1 Diabetes and High HBA1C: A Randomized Controlled Trial Demonstrating That Response to Alerts Drives Outcomes
Aims: The aim was to assess the efficacy and safety of the smart multiple daily injections (MDI) system versus MDI plus continuous glucose monitor (CGM) in people with Type 1 diabetes and HbA1c ≥ 8%. Material and Methods: After a 3‐week run‐in, 143 participants were randomized to Smart MDI or MDI + CGM. The primary endpoint was between‐group difference (Δ) in time‐in‐range (TIR) at 6 months, adjusted for baseline glycaemia and assessed for non‐inferiority (margin 7.5%). Secondary endpoints included HbA1c (non‐inferiority margin 0.4%) and superiority analyses for TIR and HbA1c. Smart MDI alerts prompt insulin bolus actions (in contrast to traditional CGM alerts), and post hoc analyses were performed to evaluate ‘alert‐responsiveness’ on glycaemia. Alert‐responsiveness findings were validated in a real‐world cohort of 5507 users. Safety endpoints were assessed. Results: At 6 months, Δ TIR between groups was 0.19 percentage points (95% confidence interval: −4.9 to 5.3), thus meeting non‐inferiority; HbA1c also met non‐inferiority (Δ: −0.13 percentage points, −0.46 to 0.19) but neither showed superiority. Post hoc analyses showed higher responders to alerts (those responding more than the median response rate of 28.3%, n = 31) had greater TIR gains than lower responders ( n = 28) (+8.12 percentage points; p = 0.04) and HbA1c reduction (−0.6 percentage points; p = 0.02). TIR benefits in higher responders were confirmed in the real‐world cohort. One episode of diabetic ketoacidosis occurred (run‐in) and one severe hypoglycaemic event occurred (control arm). Conclusions: Smart MDI is safe and non‐inferior, achieving non‐inferiority to MDI + CGM regarding TIR and HbA1c. Responding to as few as 28% of alerts resulted in glycaemic improvements.
- 19 October 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessThe Smart MDI System in People With Type 1 Diabetes and High HBA1C: A Randomized Controlled Trial Demonstrating That Response to Alerts Drives Outcomes
Aims: The aim was to assess the efficacy and safety of the smart multiple daily injections (MDI) system versus MDI plus continuous glucose monitor (CGM) in people with Type 1 diabetes and HbA1c ≥ 8%. Material and Methods: After a 3‐week run‐in, 143 participants were randomized to Smart MDI or MDI + CGM. The primary endpoint was between‐group difference (Δ) in time‐in‐range (TIR) at 6 months, adjusted for baseline glycaemia and assessed for non‐inferiority (margin 7.5%). Secondary endpoints included HbA1c (non‐inferiority margin 0.4%) and superiority analyses for TIR and HbA1c. Smart MDI alerts prompt insulin bolus actions (in contrast to traditional CGM alerts), and post hoc analyses were performed to evaluate ‘alert‐responsiveness’ on glycaemia. Alert‐responsiveness findings were validated in a real‐world cohort of 5507 users. Safety endpoints were assessed. Results: At 6 months, Δ TIR between groups was 0.19 percentage points (95% confidence interval: −4.9 to 5.3), thus meeting non‐inferiority; HbA1c also met non‐inferiority (Δ: −0.13 percentage points, −0.46 to 0.19) but neither showed superiority. Post hoc analyses showed higher responders to alerts (those responding more than the median response rate of 28.3%, n = 31) had greater TIR gains than lower responders ( n = 28) (+8.12 percentage points; p = 0.04) and HbA1c reduction (−0.6 percentage points; p = 0.02). TIR benefits in higher responders were confirmed in the real‐world cohort. One episode of diabetic ketoacidosis occurred (run‐in) and one severe hypoglycaemic event occurred (control arm). Conclusions: Smart MDI is safe and non‐inferior, achieving non‐inferiority to MDI + CGM regarding TIR and HbA1c. Responding to as few as 28% of alerts resulted in glycaemic improvements.
- Open Access
- 30 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (8) , 1-15
Real-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain
Introduction Automated insulin delivery systems are effective for the management of type 1 diabetes (T1D). However, analyses of how such effectiveness translates into real-world practice in Spain are lacking. The aim of this study was therefore to examine real-world data generated by users of the MiniMed 780G system with T1D in Spain. Methods The CareLink Personal software program was used to collect data from 16,392 users of the MiniMed 780G system. Outcomes assessed included measures of glycemic control. Comparisons were made between age groups and between pre- and post-advanced hybrid closed-loop (AHCL) system initiation. Additionally, longitudinal data from 12 months of continuous usage were analyzed. Results Overall, the mean time in range (TIR) was 75.9%, the time in tight range (TITR) was 51.0%, the time below 70 mg/dL (TB70) was 2.2%, and most users achieved international glycemic control targets with 77.4% having a TIR > 70%. Results were similar across age groups but tended to be better among users who utilized recommended optimal settings, with a TIR of 79.8%, TITR of 55.4%, and TB70 of 2.0%. Substantial improvements were observed between pre- and post-initiation of AHCL (n = 4294), with mean TIR increasing from 64.7% to 75.8% and the proportions of users achieving a TIR of > 70% more than doubling. In a longitudinal analysis of a cohort with 12 months of data (n = 6664), improvements in glycemic control were stable. Conclusions This analysis provides evidence of sustained improvements in glycemic control among users of the MiniMed 780G system in Spain, demonstrating how the use of such a system can result in large increases in the time individuals with T1D spend in range.
- 30 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (8) , 1-15
Open AccessReal-World Glucometric Outcomes of the MiniMed 780G Advanced Hybrid Closed-Loop System in Users with Type 1 Diabetes in Spain
Introduction Automated insulin delivery systems are effective for the management of type 1 diabetes (T1D). However, analyses of how such effectiveness translates into real-world practice in Spain are lacking. The aim of this study was therefore to examine real-world data generated by users of the MiniMed 780G system with T1D in Spain. Methods The CareLink Personal software program was used to collect data from 16,392 users of the MiniMed 780G system. Outcomes assessed included measures of glycemic control. Comparisons were made between age groups and between pre- and post-advanced hybrid closed-loop (AHCL) system initiation. Additionally, longitudinal data from 12 months of continuous usage were analyzed. Results Overall, the mean time in range (TIR) was 75.9%, the time in tight range (TITR) was 51.0%, the time below 70 mg/dL (TB70) was 2.2%, and most users achieved international glycemic control targets with 77.4% having a TIR > 70%. Results were similar across age groups but tended to be better among users who utilized recommended optimal settings, with a TIR of 79.8%, TITR of 55.4%, and TB70 of 2.0%. Substantial improvements were observed between pre- and post-initiation of AHCL (n = 4294), with mean TIR increasing from 64.7% to 75.8% and the proportions of users achieving a TIR of > 70% more than doubling. In a longitudinal analysis of a cohort with 12 months of data (n = 6664), improvements in glycemic control were stable. Conclusions This analysis provides evidence of sustained improvements in glycemic control among users of the MiniMed 780G system in Spain, demonstrating how the use of such a system can result in large increases in the time individuals with T1D spend in range.
- Open Access
- 30 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (8) , 1-14
Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece
Introduction Real-world studies have demonstrated the effectiveness of automated insulin delivery systems in managing people with type 1 diabetes (T1D) worldwide. However, data on the effectiveness of such systems in the management of people with T1D in Greece have previously been lacking. This retrospective analysis sought to address this by providing real-world insights into the impact of the MiniMed 780G system on the glycemic control of people with T1D in Greece. Methods Data from MiniMed 780G systems, uploaded to the CareLink Personal Software program between January 2024 and January 2025 by 2284 users with T1D in Greece, were collected and analyzed. Outcomes considered included glycemic control measures such as time spent in target ranges, glucose management indicator (GMI), and international glycemic control targets. Data were analyzed across different age groups (≤ 15 years, 16–55 years, ≥ 56 years), with additional analyses of cohorts using recommended optimal settings (ROS), users with data from before and after the initiation of the advanced hybrid closed-loop system, and users with 12 months of data. Results Across the overall cohort, the mean (standard deviation [SD]) time in range (TIR) was 75.4% (9.5%), and 59.3% of users achieved a combined target of a GMI < 7%, TIR > 70%, time below 70 mg/dl < 4%, and time below 54 mg/dl < 1%. These findings were consistent across age groups and stable over a 12-month period, but were found to be better among users with ROS. Comparing data obtained before and after the initiation of the system, mean (SD) TIR was found to increase from 65.1% (13.9%) to 74.9% (9.6%), while the proportion of users achieving a TIR of > 70% increased from 36.1 to 72.8%. Conclusion These data demonstrate that most users of the MiniMed 780G system achieve the recommended glycemic control targets.
- 30 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (8) , 1-14
Open AccessReal-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece
Introduction Real-world studies have demonstrated the effectiveness of automated insulin delivery systems in managing people with type 1 diabetes (T1D) worldwide. However, data on the effectiveness of such systems in the management of people with T1D in Greece have previously been lacking. This retrospective analysis sought to address this by providing real-world insights into the impact of the MiniMed 780G system on the glycemic control of people with T1D in Greece. Methods Data from MiniMed 780G systems, uploaded to the CareLink Personal Software program between January 2024 and January 2025 by 2284 users with T1D in Greece, were collected and analyzed. Outcomes considered included glycemic control measures such as time spent in target ranges, glucose management indicator (GMI), and international glycemic control targets. Data were analyzed across different age groups (≤ 15 years, 16–55 years, ≥ 56 years), with additional analyses of cohorts using recommended optimal settings (ROS), users with data from before and after the initiation of the advanced hybrid closed-loop system, and users with 12 months of data. Results Across the overall cohort, the mean (standard deviation [SD]) time in range (TIR) was 75.4% (9.5%), and 59.3% of users achieved a combined target of a GMI < 7%, TIR > 70%, time below 70 mg/dl < 4%, and time below 54 mg/dl < 1%. These findings were consistent across age groups and stable over a 12-month period, but were found to be better among users with ROS. Comparing data obtained before and after the initiation of the system, mean (SD) TIR was found to increase from 65.1% (13.9%) to 74.9% (9.6%), while the proportion of users achieving a TIR of > 70% increased from 36.1 to 72.8%. Conclusion These data demonstrate that most users of the MiniMed 780G system achieve the recommended glycemic control targets.
- Open Access
- 4 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 7636-7639
Impact of User Responses to Smart MDI Notifications: Insights From a Longitudinal Real‐World Study of 2604 Smart MDI System Users
- 4 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (8) , 7636-7639
Open AccessImpact of User Responses to Smart MDI Notifications: Insights From a Longitudinal Real‐World Study of 2604 Smart MDI System Users
- 20 May 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (11) , 1218-1219
Response to: Quiros et al.: Baseline Glycemic Control and AID Efficacy in Type 1 Diabetes and Pregnancy
- 20 May 2026
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 28 (11) , 1218-1219
Response to: Quiros et al.: Baseline Glycemic Control and AID Efficacy in Type 1 Diabetes and Pregnancy
- Open Access
- 2 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 35-48
Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review
Sex‐based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long‐term complications, particularly cardiovascular disease. Additionally, women face a greater economic and mental health burden related to T1D. This narrative review explores the challenges that complicate glycaemic management in women living with T1D, including hormonal influences during puberty, pregnancy and the (peri‐) menopausal period. We also summarize current available evidence on the safety and efficacy of the MiniMed™ 780G (MM780G) system in addressing these challenges for women living with T1D. Finally, recent real‐world data are reported on the absence of significant sex‐related differences in glycaemic outcomes of over 280 000 real‐world users of the MM780G, across various age groups from childhood and adolescence to the (peri‐) menopausal period.
- 2 January 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 35-48
Open AccessChallenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review
Sex‐based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long‐term complications, particularly cardiovascular disease. Additionally, women face a greater economic and mental health burden related to T1D. This narrative review explores the challenges that complicate glycaemic management in women living with T1D, including hormonal influences during puberty, pregnancy and the (peri‐) menopausal period. We also summarize current available evidence on the safety and efficacy of the MiniMed™ 780G (MM780G) system in addressing these challenges for women living with T1D. Finally, recent real‐world data are reported on the absence of significant sex‐related differences in glycaemic outcomes of over 280 000 real‐world users of the MM780G, across various age groups from childhood and adolescence to the (peri‐) menopausal period.
- Open Access
- 1 January 2026
- Published by Wiley in Pediatric Diabetes
- Vol. 2026 (1) , 1653728
Achieving Glycemic Targets in and out‐of‐School: Real‐World Data From 1341 Italian Children Using the MiniMed 780G System During Auto Mode
In this real‐world analysis, we evaluated glycemia and insulin delivery in Italian children using the MiniMed 780G system during auto mode use, comparing days with a school routine to out‐of‐school (OOS) days. Data from 1341 users, self‐reported under 16 years old and with type 1 diabetes (T1D), showed no meaningful difference in time in range (TIR) between school days (73.4%) and OOS days (72.4%), and international targets were met on average during both types of day. Minor sensor glucose variations were observed during school hours, such as a more pronounced glucose peak after breakfast and a clearer dip before lunch on school days. The insulin delivery algorithm effectively managed these fluctuations. Maintaining optimized glycemia during both school and OOS days may enhance learning and support cognitive and brain development.
- 1 January 2026
- Published by Wiley in Pediatric Diabetes
- Vol. 2026 (1) , 1653728
Open AccessAchieving Glycemic Targets in and out‐of‐School: Real‐World Data From 1341 Italian Children Using the MiniMed 780G System During Auto Mode
In this real‐world analysis, we evaluated glycemia and insulin delivery in Italian children using the MiniMed 780G system during auto mode use, comparing days with a school routine to out‐of‐school (OOS) days. Data from 1341 users, self‐reported under 16 years old and with type 1 diabetes (T1D), showed no meaningful difference in time in range (TIR) between school days (73.4%) and OOS days (72.4%), and international targets were met on average during both types of day. Minor sensor glucose variations were observed during school hours, such as a more pronounced glucose peak after breakfast and a clearer dip before lunch on school days. The insulin delivery algorithm effectively managed these fluctuations. Maintaining optimized glycemia during both school and OOS days may enhance learning and support cognitive and brain development.
- Open Access
- 28 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 2473-2476
What is the impact of an advanced hybrid closed‐loop system on weight control among people with type 1 diabetes?
- 28 December 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (3) , 2473-2476
Open AccessWhat is the impact of an advanced hybrid closed‐loop system on weight control among people with type 1 diabetes?
- Open Access
- 28 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 61-68
A narrative review of meal management with the MiniMed ™ 780G system: Evolution of dietary management in type 1 diabetes
Background: Type 1 diabetes (T1D) meal management has long relied on structured carbohydrate counting and rigid bolus timing to achieve optimal glycaemic outcomes. However, these strategies impose a cognitive burden and are difficult to sustain in daily life. This narrative review evaluates how the MiniMed™ 780G Automated Insulin Delivery (AID) system enables revisiting management strategies with simplified and flexible approaches without significantly compromising clinical efficacy. Methods: A narrative review was conducted based on published clinical studies and real‐world evidence (RWE) papers collected from MiniMed™ 780G system users. The analysis focused on meal bolusing patterns, unannounced meals, carbohydrate counting strategies, high‐fat/high‐protein diets, fasting regimens, and other meal‐related conditions. Results: Evidence suggests that the MiniMed™ 780G system provides significant flexibility in meal management without compromising glycaemic outcomes. Comparable time in range (TIR) was observed whether insulin was bolused pre‐meal or at meal start, although delaying bolusing beyond 30 min post‐meal led to greater glucose excursions. The system demonstrated the capability to compensate for missed meal boluses of up to 30 g of carbohydrates. Predefined fixed meal bolusing strategies may be more convenient for people with diabetes who are hesitant to perform precise carbohydrate counting, yet they can still achieve international glycaemic targets. Additionally, the system effectively adapts to high‐fat, high‐protein meals and fasting regimens, such as those observed during Ramadan, with minimal impact on TIR. Real‐world data from over 61 000 users confirm that adherence to the system's optimal settings (glucose target of 100 mg/dL, active insulin time 2 h) and the use of 2–3 carbohydrate ratios per day resulted in the greatest glycaemic benefit. Conclusion: The MiniMed™ 780G system shifts the paradigm of meal management in T1D from intensive self‐regulation toward automation and behavioral sustainability. These findings support broader access to AID technology by reducing reliance on precise carb counting and aligning therapy with real‐world needs.
- 28 November 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (S1) , 61-68
Open AccessA narrative review of meal management with the MiniMed ™ 780G system: Evolution of dietary management in type 1 diabetes
Background: Type 1 diabetes (T1D) meal management has long relied on structured carbohydrate counting and rigid bolus timing to achieve optimal glycaemic outcomes. However, these strategies impose a cognitive burden and are difficult to sustain in daily life. This narrative review evaluates how the MiniMed™ 780G Automated Insulin Delivery (AID) system enables revisiting management strategies with simplified and flexible approaches without significantly compromising clinical efficacy. Methods: A narrative review was conducted based on published clinical studies and real‐world evidence (RWE) papers collected from MiniMed™ 780G system users. The analysis focused on meal bolusing patterns, unannounced meals, carbohydrate counting strategies, high‐fat/high‐protein diets, fasting regimens, and other meal‐related conditions. Results: Evidence suggests that the MiniMed™ 780G system provides significant flexibility in meal management without compromising glycaemic outcomes. Comparable time in range (TIR) was observed whether insulin was bolused pre‐meal or at meal start, although delaying bolusing beyond 30 min post‐meal led to greater glucose excursions. The system demonstrated the capability to compensate for missed meal boluses of up to 30 g of carbohydrates. Predefined fixed meal bolusing strategies may be more convenient for people with diabetes who are hesitant to perform precise carbohydrate counting, yet they can still achieve international glycaemic targets. Additionally, the system effectively adapts to high‐fat, high‐protein meals and fasting regimens, such as those observed during Ramadan, with minimal impact on TIR. Real‐world data from over 61 000 users confirm that adherence to the system's optimal settings (glucose target of 100 mg/dL, active insulin time 2 h) and the use of 2–3 carbohydrate ratios per day resulted in the greatest glycaemic benefit. Conclusion: The MiniMed™ 780G system shifts the paradigm of meal management in T1D from intensive self‐regulation toward automation and behavioral sustainability. These findings support broader access to AID technology by reducing reliance on precise carb counting and aligning therapy with real‐world needs.
- Open Access
- 13 October 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (12) , e70161
Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users
Aims: The study analysed real‐world data of people with type 1 diabetes (PWT1D) using the Smart Multiple Daily Insulin (MDI) system with the aim of assessing associations between user interaction behaviours and parameters of glycaemic control to provide educational insights for optimal system use. Methods: A retrospective cohort analysis was conducted using data from 1852 PWT1D users of the Smart MDI system across 21 countries. The system comprises the InPen™ insulin injector, Simplera™ CGM, and the InPen™ phone application. Users were included if they had at least 10 days of InPen and CGM data. Glycaemic outcomes were correlated with user interaction, focusing on responses to missed dose alerts (MDA) and correct high glucose alerts (CHGA). Results: The mean time in range (TIR) was 55.7%, with users responding with a bolus dose to 49.3% of MDA and 46.6% of CHGA. However, those users who responded within 1 h to over 75% of alerts with a bolus dose achieved higher TIRs of 67.2% (MDA) and 71.5% (CHGA). Prompt responses (within 10 min) showed greater TIR. The study highlighted significant associations between alert responsiveness and better glycaemic outcomes without increased hypoglycaemia risk. Conclusions: User engagement with the Smart MDI system is crucial for optimal glycaemic outcomes. The study underscores the need for structured education on system use and alert responses. While causality cannot be confirmed, the findings suggest that proactive user interactions contribute to meeting glycaemic targets. Further research is needed to explore these relationships and enhance educational strategies.
- 13 October 2025
- Published by Wiley in Diabetic Medicine
- Vol. 42 (12) , e70161
Open AccessInsights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users
Aims: The study analysed real‐world data of people with type 1 diabetes (PWT1D) using the Smart Multiple Daily Insulin (MDI) system with the aim of assessing associations between user interaction behaviours and parameters of glycaemic control to provide educational insights for optimal system use. Methods: A retrospective cohort analysis was conducted using data from 1852 PWT1D users of the Smart MDI system across 21 countries. The system comprises the InPen™ insulin injector, Simplera™ CGM, and the InPen™ phone application. Users were included if they had at least 10 days of InPen and CGM data. Glycaemic outcomes were correlated with user interaction, focusing on responses to missed dose alerts (MDA) and correct high glucose alerts (CHGA). Results: The mean time in range (TIR) was 55.7%, with users responding with a bolus dose to 49.3% of MDA and 46.6% of CHGA. However, those users who responded within 1 h to over 75% of alerts with a bolus dose achieved higher TIRs of 67.2% (MDA) and 71.5% (CHGA). Prompt responses (within 10 min) showed greater TIR. The study highlighted significant associations between alert responsiveness and better glycaemic outcomes without increased hypoglycaemia risk. Conclusions: User engagement with the Smart MDI system is crucial for optimal glycaemic outcomes. The study underscores the need for structured education on system use and alert responses. While causality cannot be confirmed, the findings suggest that proactive user interactions contribute to meeting glycaemic targets. Further research is needed to explore these relationships and enhance educational strategies.